Company: APM
Filing Date: 2025-10-14
Form Type: 424B5
Source: 0001213900-25-098635
Chunk: 23

Company: Aptorum Group Ltd
Filing Date: 2025-10-14
Form: 424B5
Chunk 23
---
300 cancer cell lines and showed positive results in a number of cancer types including
in particular colorectal cancer, leukemia and lymphoma, etc.

Similar to our previous findings
against neuroblastoma cell lines, SACT-1 exhibits similar anti-tumor efficacy across one or more other major cancer types, including but
not limited to colorectal cancer, leukemia and lymphoma cell lines. As a result, in addition to treating neuroblastoma, SACT-1 may have
potential applications in the treatment of other cancers. Based on this discovery, we plan to carry out further in vivostudies
to study the efficacy of SACT-1 over other types of cancers to maximize the potential of SACT-1. Based on the initial 22-day data of a
recent study we conducted in a xenograft mouse model of neuroblastoma, SACT-1 was orally administered daily at 60mg/kg in combination
of SOC chemotherapy brought a statistically significant tumor shrinkage (unpaired student’s t-test, p<0.01) from Day 15 to Day
22, compared to the control group which received SOC only. The combination reduced the tumor size by up to 54.2% in the first 22 days
compared with the control (SOC only). SACT-1 appears to be effective in accelerating the effect of the SOC in early time points (from
Day 1 – 7 vs control). This further supports our earlier in vitroobservation that SACT-1 promotes tumor DNA damage
and tumor cell death.

<div align='center'>S-12</div>

Figure 5 Figure 5: 22 days data of in vivostudies in a xenograft mouse model of neuroblastoma

| ** | Unpaired student’s t-test, p<0.01, n=8 (based on 
 initial 22 days period)                          |

In September 2021, we announced that we received clearance from the US FDA regarding the IND application to initiate clinical trials of SACT-1. In January 2022, we further announced that the completion of our Phase I clinical trial for assessing relative bioavailability and food effect of SACT-1, and no serious adverse events were observed. SACT-1’s Phase 1 clinical trial is an Open-label Randomized, Single Cross Over Bioavailability and Food Effect Study of SACT-1 in healthy adult volunteers. In additions, the US FDA has granted Orphan Drug Designation to SACT-1 in January